Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate.
DeWeese
T L
TL
Johns Hopkins Oncology Center, Division of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Song
D Y
DY
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013997:Time Factors
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal